# Intravenous Immunoglobulin and Prednisolone for RPL After ART.

> **NCT04701034** · PHASE2 · COMPLETED · sponsor: **Aalborg University Hospital** · enrollment: 80 (actual)

## Conditions studied

- Habitual Abortion
- Recurrent Pregnancy Loss
- Fertility Disorders
- Miscarriage

## Interventions

- **DRUG:** Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)
- **DRUG:** Prednisolone Tablets
- **DRUG:** Human Albumin Solution
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT04701034
- **Lead sponsor:** Aalborg University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-28
- **Primary completion:** 2024-04-18
- **Final completion:** 2024-04-18
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701034, "Intravenous Immunoglobulin and Prednisolone for RPL After ART.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04701034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*